163210-03-5

Usage

Ester derivative

1-Piperidinecarboxylic acid

Common use

Precursor in the synthesis of various pharmaceuticals and organic compounds

Presence of functional group

3-bromophenylmethylene

Suitability

Preparation of antipsychotic and antidepressant medications

Application

Organic synthesis and medicinal chemistry research

Use as reagent

Formation of carbon-carbon and carbon-heteroatom bonds

Potential

Building block in the development of new drugs and bioactive substances

Upstream product

• 823-78-9 meta-bromobenzyl bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 128833-03-4 P-[(3-bromophenyl)methyl]phosphonic acid diethyl ester 
• 95902-10-6 (3-bromobenzyl)(triphenyl)phosphonium bromide 

Downstream Products

• 1177559-56-6 1,1-dimethylethyl 4-[(3-bromophenyl)methyl]-1-piperidinecarboxylate 
• 1178903-98-4 tert-butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylidene)piperidine-1-carboxylate 
• 584555-70-4 4-[(3-bromophenyl)methylene]piperidine hydrochloride 
• 1179344-49-0 N-{[1,6-diethyl-4-(tetrahydro-1H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-2-[3'-(4-piperidinylmethyl)-3-biphenylyl]acetamide 
• 1177559-55-5 tert-butyl4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperidine-1-carboxylate 
• 584555-56-6 C₂₂H₂₆N₂O₂ 
• 584555-96-4 C₁₂H₁₄BrN 
• 766505-87-7 C₁₈H₂₈N₂ 
• 584555-58-8 C₂₃H₃₆N₂O₂ 
• 1123543-65-6 C₂₃H₂₉N₂O₂⁽¹⁺⁾*I^(1-) 
• 584555-84-0 C₂₈H₂₈N₂O₂ 
• 584555-36-2 C₃₀H₃₀N₂O 
• 584555-40-8 C₂₈H₃₀N₂O₂ 
• 586412-00-2 C₂₉H₃₈N₄O 

Relevant academic research and scientific papers

BIFUNCTIONAL COMPOUNDS

The invention provides a bifunctional compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein said Targeting Ligand, Linker and Degron are as described herein.

3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands-Part II

A series of 5-(piperidinylethyloxy)quinoline 5-HT1 receptor ligands have been studied by elaboration of the series of dual 5-HT1-SSRIs reported previously. These new compounds display a different in vitro pharmacological profile with potent affinity across the 5-HT1A, 5-HT1B and 5-HT1D receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles and CNS penetration.